肺癌的免疫治疗进展  

Advances in immunotherapy for lung cancer

作　　者：马美丽[1] 钟华[1] 钱嘉琳[1] 滕家俊[1] 韩宝惠[1] 

机构地区：[1]上海交通大学附属胸科医院呼吸内科,上海200030

出　　处：《世界临床药物》2015年第4期217-222,共6页World Clinical Drug

摘　　要：肺癌是全球范围内发病率和死亡率居前的恶性肿瘤之一。传统化疗有效率低,靶向治疗对于敏感突变者疗效好,但远期耐药很难避免。新近抗原特异性肿瘤疫苗等多种新型抗肿瘤免疫治疗药物针对肺癌的临床研究进展显著,本文综述多种免疫治疗药物在肺癌免疫治疗中的应用研究。Lung cancer is the leading cause of cancer-related death worldwide. Now the traditional cytotoxic agents have remained the mainstay of systemic therapy for this disease. With the identification of novel immune cancer-specific aberrancies, the immunotherapy has garnered increasing attention as an attractive target, which has the potential to improve outcomes. Recent advances in the understanding of immunology and antitumor immune responses have led to the development of new immunotherapies, including vaccination approaches and monoclonal antibodies which inhibit immune checkpoint pathways. These strategies have shown the activity in melanoma and the immune-based treatments in various stages of evaluation for NSCLC as well. This review provides the new development of immunotherapeutic agents for lung cancer.

关 键 词：非小细胞肺癌(NSCLC) 免疫治疗 疫苗 

分 类 号：R734.2[医药卫生—肿瘤] R459.9[医药卫生—临床医学]